EPIMED RESEARCH

Intellectual Property Experts in Life Sciences

    • Blog
    • Home
    • Technologies Available for licensing
  • Acorda Therapeutics, Inc. v. Alkermes PLC

    U.S. Court of Appeals for the Federal Circuit Opinions Docket: 23-2374  Opinion Date: July 25, 2025 Acorda Therapeutics, Inc. developed Ampyra®, a drug for multiple sclerosis, and had a licensing agreement with Alkermes PLC, which owned a patent for Ampyra’s active ingredient. The patent expired in July 2018, but Acorda continued to make royalty payments to Alkermes…

    epimedresearch

    July 27, 2025
    Uncategorized
  • EYE THERAPIES, LLC v. SLAYBACK PHARMA LLC 

    Court: U.S. Court of Appeals for the Federal Circuit Docket: 23-2173 Opinion Date: June 30, 2025 Eye Therapies, LLC owns the ‘742 patent, which describes a method to reduce eye redness using a low-concentration dose of brimonidine. The independent claims of the patent specify that the method consists essentially of administering brimonidine at certain concentrations. During patent prosecution,…

    epimedresearch

    July 7, 2025
    Uncategorized
  • UNITED SERVICES AUTOMOBILE ASSOCIATION v. PNC BANK N.A.

    Docket: 23-1639  Opinion Date: June 12, 2025 Judge: Todd Hughes United Services Automobile Association (USAA) owns U.S. Patent No. 10,402,638, which is directed to remote check deposit technology. The patent describes a system where a customer uses a personal mobile device to take a picture of a check and transmit the image to a financial institution. The system…

    epimedresearch

    June 13, 2025
    Uncategorized
  • AGILENT TECHNOLOGIES, INC. v. SYNTHEGO CORP.

    Court: U.S. Court of Appeals for the Federal Circuit Docket: 23-2186  Opinion Date: June 11, 2025 Judge: Sharon Prost Agilent Technologies, Inc. appealed two final written decisions by the Patent Trial and Appeal Board (Board) that determined all claims of U.S. Patent Nos. 10,337,001 and 10,900,034 to be unpatentable. The patents in question relate to CRISPR-Cas systems for gene…

    epimedresearch

    June 11, 2025
    Uncategorized
    intellectual-property, law, litigation, news, patent, politics, supreme-court
  • Supreme Court Case Amgen Inc. v. Sanofi Summary and Its Implication in Biotech Patents

    The United States Supreme Court case, Amgen Inc. v. Sanofi, has significant implications for patent law, particularly in the realm of pharmaceuticals and biotechnology. This case revolved around the enablement requirement of the Patent Act, 35 U.S.C. § 112 (a). Background Amgen and Sanofi, two pharmaceutical giants, each obtained a patent in 2011 for the antibody…

    epimedresearch

    May 20, 2023
    Uncategorized
    ai, intellectual-property, ip, patent, patents
  • The Impact of United States v. Arthrex Inc. on PTAB Proceedings

    The Supreme Court’s decision in United States v. Arthrex Inc. has limited impact on the structure of the Patent Trial and Appeal Board (PTAB) and the appointment of Administrative Patent Judges (APJs) due to the Courts’ narrow remedy and proposed fix of adding a layer of Director review.  The case, decided in June 2021, addressed the…

    epimedresearch

    December 17, 2021
    Uncategorized
    news, patent, patents, politics, ptab, supreme-court, uspto
  • The Minerva Surgical, Inc. v. Hologic, Inc. Case: A Landmark Decision in Patent Law

    The Supreme Court’s decision in Minerva Surgical, Inc. v. Hologic, Inc. has far-reaching implications for patent law, particularly concerning the doctrine of assignor estoppel. This case, decided in June 2021, centered around the question of whether the doctrine of assignor estoppel should be retained, modified, or eliminated altogether. This blog post provides an overview of the case,…

    epimedresearch

    July 15, 2021
    Uncategorized
    intellectual-property, ip, law, patent, patents
  • Understanding the Impact of Thryv, Inc. v. Click-to-Call Technologies on Patent Litigation

    The Supreme Court’s decision in Thryv, Inc. v. Click-to-Call Technologies has significant implications for the landscape of patent litigation, particularly concerning the doctrine of inter partes review (IPR). This case, decided in April 2020, addressed the question of whether the Patent Trial and Appeal Board (PTAB) can determine whether a petition for IPR is timely…

    epimedresearch

    December 12, 2019
    Uncategorized
    intellectual-property, ip, ipr, law, patent, patents, uspto
  • Doctrine of Repair and Reconstruction

    Doctrine of Repair and Reconstruction

    Doctrine of repair and reconstruction, or repair doctrine, in U.S. patent law allows a person who is authorized to produce, use, or distribute a patented item to repair and replace unpatented components.  Essentially, the owner of a patented property has a lawful right to repair or replace his/her property.   The repair and reconstruction doctrine was established…

    epimedresearch

    May 16, 2018
    Uncategorized
  • The development and commercialization plan requirement in a license agreement

    The development and commercialization plan requirement in a license agreement

    Many technology-centric start-ups are based on the technologies generated from universities or from government funded projects (in places such as national labs, projects in non-profit institutes, or even small companies).   As an entrepreneur, if you want to start a technology based company, one place to look for the opportunities is the technology portfolios managed by the…

    epimedresearch

    March 9, 2018
    Uncategorized
Previous Page
1 2 3 4 … 6
Next Page

EPIMED RESEARCH

A full-service IP and FDA firm specializing in intellectual property strategy and management, technology commercialization, and FDA regulatory compliance. We help to protect and maximize the value of your most important asset.

Bellevue
Washington

Email us

Info@epimedresearch.com

LinkedIn

Copyright@2012 EpiMed LLC. All rights reserved

  • Subscribe Subscribed
    • EPIMED RESEARCH
    • Already have a WordPress.com account? Log in now.
    • EPIMED RESEARCH
    • Subscribe Subscribed
    • Sign up
    • Log in
    • Report this content
    • View site in Reader
    • Manage subscriptions
    • Collapse this bar